Skip to main
CVAC
CVAC logo

CureVac B.V (CVAC) Stock Forecast & Price Target

CureVac B.V (CVAC) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

CureVac NV is strategically positioned within the competitive mRNA landscape, capitalizing on the high value generated by COVID-19 vaccines and the anticipated broader applications of mRNA technology. The company has established a significant collaboration with GSK, focusing on developing advanced vaccine candidates for seasonal and avian influenza, alongside oncology and molecular therapies targeting various diseases. Additionally, the advancement of its development programs demonstrates a commitment to innovation, reinforcing the positive outlook for CureVac's future growth and potential market success.

Bears say

CureVac NV is expected to continue incurring net losses until at least product approval and commercialization, potentially extending into the early launch phase. The company faces significant competitive risks as it may struggle to compete effectively against established and in-development candidates in the mRNA vaccine space. Furthermore, legal and intellectual property risks could further exacerbate revenue generation challenges, potentially impacting future sales significantly.

CureVac B.V (CVAC) has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CureVac B.V and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CureVac B.V (CVAC) Forecast

Analysts have given CureVac B.V (CVAC) a Hold based on their latest research and market trends.

According to 3 analysts, CureVac B.V (CVAC) has a Hold consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CureVac B.V (CVAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.